MediciNova

San Diego, United States Founded: 2000 • Age: 26 yrs Listed
Small-molecule therapeutics are developed for asthma, COPD, and neurologic diseases.

About MediciNova

MediciNova is a publicly listed company based in San Diego (United States) founded in 2000 by Yuichi Iwaki. Small-molecule therapeutics are developed for asthma, COPD, and neurologic diseases. MediciNova has raised $83.94 million across 5 funding rounds from investors including Sumitomo Mitsui Banking Corporation, CDIB Capital Group and Dr.Ci:Labo. The company has 13 employees. MediciNova has completed 2 acquisitions, including AviGen and Aviagen. Its chief executive, as recorded, is Yuichi Iwaki. Its focus areas include Life Sciences, Pulmonology, Drugs and COPD and Asthma. Its competitors include TFF Pharmaceuticals, Theravance Biopharma and Elastrin; 2 of its 3 listed competitors have raised funding.

Company details

MediciNov is a biopharmaceutical company that develops novel, small-molecule therapeutics for the treatment of diseases with unmet needs. It holds rights to a diversified portfolio of clinical and preclinical product candidates. Their pipeline includes six clinical-stage compounds for the treatment of acute exacerbations of asthma, COPD exacerbations, multiple sclerosis, and other neurologic conditions, asthma, interstitial cystitis, solid tumor cancers, Generalized Anxiety Disorder, preterm labor, and urinary incontinence and two preclinical-stage compounds for the treatment of thrombotic disorders. Focusing on its two prioritized product candidates, MN-221, for the treatment of acute exacerbations of asthma and chronic obstructive pulmonary disease exacerbations, and ibudilast (MN-166AV411).

  • Headquarters San Diego, United States
  • Employees 13
  • Founders Yuichi Iwaki
  • Stage Public
  • Sectors
    Healthcare
  • Website category Health · Biotechnology and Pharmaceuticals
  • Website medicinova.com
  • Social LinkedIn
  • Legal Name Medicinova, Inc.
Operational Areas
Key Metrics
  • Annual Revenue
    $409.66 K (USD)
    as on Dec 31, 2025
  • Net Profit
    -$12 M (USD)
    -8.58
    as on Dec 31, 2025
  • EBITDA
    -$13.09 M (USD)
    -3.44
    as on Dec 31, 2025
  • Total Equity Funding
    $83.94M (USD)

    in 5 rounds

  • Latest Funding Round
    $20M (USD), Post-IPO

    Jan 2021

  • Investors
  • Employee Count
    13
  • Investments & Acquisitions
    AviGen

    & 1 more

Funding Insights of MediciNova

MediciNova has successfully raised a total of $83.94M across 5 strategic funding rounds. The most recent funding activity was a Post-IPO round of $20 million completed in January 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding $83.94M
  • Total Rounds 5
  • Last Round Post-IPO β€” $20M
  • First Round $10M

    (Jun 2000)

  • Investors Count 15

All 5 funding rounds of MediciNova with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Jan 2021$20MPost-IPO––
Aug 2012$1MPost-IPO––
Sep 2004$44.82MSeries C––
Jun 2004$29.12MSeries B––
Jun 2000$10MSeries A––
–
Valuation history

15 investors in total: 15 institutional.

Investors in MediciNova

MediciNova has secured backing from 15 investors, including institutional and venture fund investors. Prominent investors backing the company include Sumitomo Mitsui Banking Corporation, CDIB Capital Group and Dr.Ci:Labo.

All
Venture Fund
Institutional
InvestorDescriptionFounded YearDomainLocation
aspirecapital.com
aquarimco.com
Sector-agnostic investments are made in early-stage Asia Pacific startups.
1959cdibcapitalgroup.comTaipei, Taiwan
VC firm investing in Japan and the US
nvcc.co.jpChiyoda City, Japan
Seed and Early stage VC firm investing in Japan
ut-ec.co.jpTokyo, Japan
Growth-stage healthcare companies are invested in by EW Healthcare Partners.
ewhealthcare.comNew York, United States
poscobioventures.com
Online slot gaming services are offered by ng24h platform.
nifventures.com
Japan-focused firm for opportunistic value investing and portfolio management strategies.
20153dipartners.comSingapore, Singapore
mizuho-sc.com
Premium access

Investor details for MediciNova

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

People of MediciNova

1 people are tracked at MediciNova (1 in leadership); the tracked headcount is 13.

NameRoleGroup
Yuichi Iwaki
Founder & CEOLeadership
Premium access

Complete people profiles for MediciNova

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

IPO & Listings of MediciNova

MediciNova is a publicly listed company on the NASDAQ with ticker symbol MNOV in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

  • IPO date16 Jul 2013
  • Listed onTSE: 4875
  • Listed entityMediciNova, Inc.
  • Exchange sectorHealth technology
  • ISINUS58468P2065
  • Share price$1.50 (-2.6% on the day) · 2026-10-13
  • Market capitalisation$73.8M
  • EPS (diluted, trailing year)$-0.22
  • Volume (last session)34,800

Financials of MediciNova

Exchange-reported annual figures
YearRevenueNet incomeEBITDA
2025$409,660-$12.0M-$13.1M
2024-$11.1M-$12.7M
2023$1.0M-$8.6M-$9.9M
2022-$14.1M-$14.4M
2021$4.0M-$10.1M-$10.2M
Premium access

Detailed financial statements for MediciNova

Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.

  • Statement rows
  • Financial ratios
  • Five-year trends
  • Downloads

Verified entity values are shown only after access is granted.

Investments & Acquisitions by MediciNova

MediciNova has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include AviGen and Aviagen.

Acquisitions
Company NameDescriptionDomainLocationFoundedAcquiredAmount
Gene therapy products are developed for inherited and acquired diseases.
avigen.comAlameda, United States1992Feb 2009$37M
Poultry breeding stock is supplied globally by Aviagen.
aviagen.comHuntsville, United States1923Dec 2008β€’β€’β€’β€’
Premium access

Complete acquisition details for MediciNova

Acquired stakes, deal sources and the complete acquisition history require an active premium plan.

  • Acquired stakes
  • Deal sources
  • Complete history
  • Exports

Verified entity values are shown only after access is granted.

Timeline of MediciNova

6 dated milestones of MediciNova across 21 years, from founding to its latest funding, stage changes and deals.

  1. Founded MediciNova is founded.
  2. Funding First funding round of $10.0M.
  3. Acquisition Acquires Aviagen.
  4. Acquisition Acquires AviGen.
  5. IPO Lists on the stock exchange (IPO).
  6. Funding Latest funding round, Post-IPO, of $20.0M.

Competitors of MediciNova

MediciNova has 3 listed competitors in our database, 2 of them funded. They include TFF Pharmaceuticals, Theravance Biopharma and Elastrin.

Company NameDomainFoundedHQ LocationTotal fundingEmployeesDescription
tffpharma.com2018Austin, United States$22.17M15
Developer of inhalation products for chronic respiratory diseases
theravance.com2001Francisco, United States99
Therapeutics for inflammatory and immunological diseases are developed.
elastrin.com2017Simpsonville, United States$17.25M
Developer of therapeutic targets related to arterial and lung diseases
Premium access

Detailed competitors of MediciNova

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

  • Full competitor set
  • Operating metrics
  • Benchmarks
  • Competitive positioning

Verified entity values are shown only after access is granted.

Web traffic of MediciNova

The website of MediciNova (medicinova.com) receives about 3.5K visits a month and ranks #5,782,921 among all websites worldwide, #6,248 in Biotechnology and Pharmaceuticals.

  • Monthly visits
    3.5K

    ▲ 21% vs previous month

  • Unique visitors
    1.2K

    per month

  • Global rank
    #5,782,921

    among all websites

  • Category rank
    #6,248

    Health · Biotechnology and Pharmaceuticals

Similar websites

Websites whose visitors overlap most with MediciNova. Affinity shows how closely the audiences match.

WebsiteDomainAudience affinityMonthly visitsGlobal rankProfile
medincell.com
100%
8.5K#1,508,006View details
debiopharm.com
98%
15.1K#1,818,608View details
cambrex.com
97%
35K#883,665View details
pelotontherapeutics.com
96%
View details
mabvax.com
95%
View details
β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’.comβ€’β€’%β€’.β€’M#‒‒‒‒‒–
β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’.comβ€’β€’%β€’.β€’M#‒‒‒‒‒–
β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’.comβ€’β€’%β€’.β€’M#‒‒‒‒‒–
Premium access

All 14 similar websites and full traffic analytics for MediciNova

The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.

  • 14 similar websites
  • Audience overlap
  • Engagement analytics
  • Traffic by brand

Verified entity values are shown only after access is granted.

Top companies in Pulmonology

3 companies that operate in the same segment as MediciNova (Pulmonology) in United States, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
Developer of novel protein-based therapeutics using machine learning and biological engineering
2018Somerville, Massachusetts, United StatesUSD 693 M329
Portable oxygen concentrators are supplied for respiratory therapy needs.
2001Goleta, California, United StatesUSD 51.65 MUSD 348.67 M766
Robotic microsurgical systems for endoscopy are developed.
2007Redwood City, California, United StatesUSD 733.62 M91
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Medicinova

Premium access

Complete news archive for MediciNova

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about MediciNova

MediciNova was founded in 2000.

MediciNova is headquartered in San Diego, United States. It is registered at San Diego, California, United States.

Yuichi Iwaki is the CEO of MediciNova, as recorded in our data. They have also founded this company.

MediciNova is a funded company, having raised a total of $83.94M across 5 funding rounds to date. The company's 1st funding round was a Series A of $10M, raised on Jun 2000.

MediciNova has 13 employees.

Annual revenue of MediciNova is $409.66K as on Dec 31, 2025.

MediciNov is a biopharmaceutical company that develops novel, small-molecule therapeutics for the treatment of diseases with unmet needs. It holds rights to a diversified portfolio of clinical and preclinical product candidates. Their pipeline includes six clinical-stage compounds for the treatment of acute exacerbations of asthma, COPD exacerbations, multiple sclerosis, and other neurologic conditions, asthma, interstitial cystitis, solid tumor cancers, Generalized Anxiety Disorder, preterm labor, and urinary incontinence and two preclinical-stage compounds for the treatment of thrombotic disorders. Focusing on its two prioritized product candidates, MN-221, for the treatment of acute exacerbations of asthma and chronic obstructive pulmonary disease exacerbations, and ibudilast (MN-166AV411).

MediciNova's top competitors include TFF Pharmaceuticals, Theravance Biopharma and Elastrin.

Yes, MediciNova is publicly traded on NASDAQ under the ticker symbol MNOV.

MediciNova has made 2 acquisitions, including AviGen, and Aviagen.

MediciNova has 15 investors. Key investors include Sumitomo Mitsui Banking Corporation, CDIB Capital Group, Dr.Ci:Labo, 3D Investment Partners, and Aspire Capital.

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available